IDEAS home Printed from https://ideas.repec.org/a/wly/riskan/v40y2020i6p1244-1257.html

Quantifying Human Health Risks from Virginiamycin Use in Food Animals in China

Author

Listed:
  • Louis Anthony Cox
  • Douglas A. Popken
  • Jian Sun
  • Xiao‐ping Liao
  • Liang‐Xing Fang

Abstract

Virginiamycin (VM), a streptogramin antibiotic, has been used to promote healthy growth and treat illnesses in farm animals in the United States and other countries. The combination streptogramin Quinupristin‐Dalfopristin (QD) was approved in the United States in 1999 for treating patients with vancomycin‐resistant Enterococcus faecium (VREF) infections. Many chickens and swine test positive for QD‐resistant E. faecium, raising concerns that using VM in food animals might select for streptogramin‐resistant strains of E. faecium that could compromise QD effectiveness in treating human VREF infections. Such concerns have prompted bans and phase‐outs of VM as growth promoters in the United States and Europe. This study quantitatively estimates potential human health risks from QD‐resistant VREF infections due to VM use in food animals in China. Plausible conservative (risk‐maximizing) quantitative risk estimates are derived for future uses, assuming 100% resistance to linezolid and daptomycin and 100% prescription rate of QD to high‐level (VanA) VREF‐infected patients. Up to one shortened life every few decades to every few thousand years might occur in China from VM use in animals, although the most likely risk is zero (e.g., if resistance is not transferred from bacteria in food animals to bacteria infecting human patients). Sensitivity and probabilistic uncertainty analyses suggest that this conclusion is robust to several data gaps and uncertainties. Potential future human health risks from VM use in animals in China appear to be small or zero, even if QD is eventually approved for use in human patients.

Suggested Citation

  • Louis Anthony Cox & Douglas A. Popken & Jian Sun & Xiao‐ping Liao & Liang‐Xing Fang, 2020. "Quantifying Human Health Risks from Virginiamycin Use in Food Animals in China," Risk Analysis, John Wiley & Sons, vol. 40(6), pages 1244-1257, June.
    • Handle: RePEc:wly:riskan:v:40:y:2020:i:6:p:1244-1257
    DOI: 10.1111/risa.13466
    as

    Download full text from publisher

    File URL: https://doi.org/10.1111/risa.13466
    Download Restriction: no
    File URL: https://libkey.io/10.1111/risa.13466?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    References listed on IDEAS

    as
    1. Louis A. Cox & Douglas A. Popken, 2004. "Quantifying Human Health Risks from Virginiamycin Used in Chickens," Risk Analysis, John Wiley & Sons, vol. 24(1), pages 271-288, February.
    2. W. Kip Viscusi & Joel Huber & Jason Bell, 2014. "Assessing Whether There Is A Cancer Premium For The Value Of A Statistical Life," Health Economics, John Wiley & Sons, Ltd., vol. 23(4), pages 384-396, April.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Patrick Carlin & Brian E. Dixon & Kosali I. Simon & Ryan Sullivan & Coady Wing, 2022. "How Undervalued is the Covid-19 Vaccine? Evidence from Discrete Choice Experiments and VSL Benchmarks," NBER Working Papers 30118, National Bureau of Economic Research, Inc.
    2. Vimefall Elin & Persson Mattias & Olofsson Sara & Hultkrantz Lars, 2022. "Is prevention of suicide worth less? A comparison of the value per statistical life," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 23(2), pages 261-275, March.
    3. Louis Anthony (Tony) Cox Jr & Douglas A. Popken, 2010. "Assessing Potential Human Health Hazards and Benefits from Subtherapeutic Antibiotics in the United States: Tetracyclines as a Case Study," Risk Analysis, John Wiley & Sons, vol. 30(3), pages 432-457, March.
    4. Rheinberger, Christoph M. & Herrera-Araujo, Daniel & Hammitt, James K., 2016. "The value of disease prevention vs treatment," Journal of Health Economics, Elsevier, vol. 50(C), pages 247-255.
    5. Hammitt, James K. & Herrera-Araujo, Daniel, 2018. "Peeling back the onion: Using latent class analysis to uncover heterogeneous responses to stated preference surveys," Journal of Environmental Economics and Management, Elsevier, vol. 87(C), pages 165-189.
    6. S. Olofsson & U.-G. Gerdtham & L. Hultkrantz & U. Persson, 2018. "Measuring the end-of-life premium in cancer using individual ex ante willingness to pay," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 19(6), pages 807-820, July.
    7. Louis Anthony Cox & Douglas A. Popken, 2004. "Bayesian Monte Carlo Uncertainty Analysis of Human Health Risks from Animal Antimicrobial Use in a Dynamic Model of Emerging Resistance," Risk Analysis, John Wiley & Sons, vol. 24(5), pages 1153-1164, October.
    8. Louis Anthony (Tony) Cox & Djangir Babayev & William Huber, 2005. "Some Limitations of Qualitative Risk Rating Systems," Risk Analysis, John Wiley & Sons, vol. 25(3), pages 651-662, June.
    9. Lisa A. Robinson & James K. Hammitt, 2016. "Valuing Reductions in Fatal Illness Risks: Implications of Recent Research," Health Economics, John Wiley & Sons, Ltd., vol. 25(8), pages 1039-1052, August.
    10. Louis Anthony (Tony) Cox, Jr. & Douglas A. Popken & Jeremy J. Mathers, 2009. "Human Health Risk Assessment of Penicillin/Aminopenicillin Resistance in Enterococci Due to Penicillin Use in Food Animals," Risk Analysis, John Wiley & Sons, vol. 29(6), pages 796-805, June.
    11. Hammitt, James K. & Herrera-Araujo, Daniel & Rheinberger, Christoph, 2016. "The Value of Cancer Prevention vs Treatment," TSE Working Papers 16-628, Toulouse School of Economics (TSE).
    12. Jytte Seested Nielsen & Susan Chilton & Hugh Metcalf, 2019. "Improving the risk–risk trade-off method for use in safety project appraisal responses," Environmental Economics and Policy Studies, Springer;Society for Environmental Economics and Policy Studies - SEEPS, vol. 21(1), pages 61-86, January.
    13. Cropper, Maureen L. & Joiner, Emily & Krupnick, Alan, 2023. "Revisiting the Environmental Protection Agency’s Value of a Statistical Life," RFF Working Paper Series 23-30, Resources for the Future.
    14. Tigran Melkonyan & Zvi Safra & Sinong Ma, 2021. "Justice in an uncertain world: Evidence on donations to cancer research," Journal of Risk and Uncertainty, Springer, vol. 62(3), pages 281-311, June.
    15. Anna Alberini & Milan Ščasný, 2021. "On the validity of the estimates of the VSL from contingent valuation: Evidence from the Czech Republic," Journal of Risk and Uncertainty, Springer, vol. 62(1), pages 55-87, February.
    16. H. Gregg Claycamp, 2006. "Rapid Benefit‐Risk Assessments: No Escape from Expert Judgments in Risk Management," Risk Analysis, John Wiley & Sons, vol. 26(1), pages 147-156, February.
    17. Gentry, Elissa Philip & Viscusi, W. Kip, 2016. "The fatality and morbidity components of the value of statistical life," Journal of Health Economics, Elsevier, vol. 46(C), pages 90-99.
    18. Mark Schneider, 2019. "A Bias Aggregation Theorem," Working Papers 19-03, Chapman University, Economic Science Institute.
    19. Sara Olofsson & Ulf G. Gerdtham & Lars Hultkrantz & Ulf Persson, 2019. "Dread and Risk Elimination Premium for the Value of a Statistical Life," Risk Analysis, John Wiley & Sons, vol. 39(11), pages 2391-2407, November.
    20. Cong Gian & Sumedha Gupta & Kosali Simon & Ryan Sullivan & Coady Wing, 2024. "Do workers undervalue COVID-19 risk? Evidence from wages and death certificate data," Journal of Risk and Uncertainty, Springer, vol. 69(3), pages 281-321, December.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:wly:riskan:v:40:y:2020:i:6:p:1244-1257. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Wiley Content Delivery (email available below). General contact details of provider: https://doi.org/10.1111/(ISSN)1539-6924 .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.